Fig. 53From: Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and β-amyloid inhibitors for Alzheimer’s diseaseReversible (R) and irreversible (I) MAO-A/B inhibitorsBack to article page